Journal of Immunology Research / 2015 / Article / Fig 5

Research Article

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Figure 5

Aggregates could not enhance ADA production through faster antigen internalization or degradation if high affinity epitopes are already present in nonaggregated TPP. Simulated levels of nonaggregated and aggregated TPP in endosome, epitopes in endosome, MHC II-peptide complex on cell surface, and ADA production are shown for ((a)–(d)) original internalization (IR0 = 14.4 day−1) and degradation (DR0 = 17.28 day−1) rate for nonaggregated adalimumab [47, 48], ((e)–(h)) 16.6IR0 and DR0 for hypothetical aggregated form, and ((i)–(l)) IR0 and 16.6DR0 for hypothetical aggregated form. ADA production has the same definition and dose has the same value as in Figure 4.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.